

CASE REPORT

Volume 15 Issue 2 2020

DOI: 10.21315/aos2020.15.2.425

ARTICLE INFO

Submitted: 30/10/2019

Accepted: 06/09/2020

Online: 24/12/2020

Extensive Basal Cell Adenocarcinoma Involving Minor Salivary Gland of the Hard Palate: A Rare Entity

Farahlina Baba^a, Ahmad Hadif Zaidin Samsudin^{b,d}, Wan Azman Wan Sulaiman^{c,d}, Wan Faiziah Wan Abdul Rahman^{a,d}, Nur Asyilla Che Jalil^{a,d*}

^aDepartment of Pathology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

^bDepartment of Radiology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

^cReconstructive Sciences Unit, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

^dHospital Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

*Corresponding author: asyilla@usm.my

To cite this article: Baba F, Samsudin AHZ, Wan Sulaiman WA, Wan Abdul Rahman WF, Che Jalil NA (2020). Extensive basal cell adenocarcinoma involving minor salivary gland of the hard palate: A rare entity. *Arch Orofac Sci*, 15(2): 197–204. <https://doi.org/10.21315/aos2020.15.2.425>

To link to this article: <https://doi.org/10.21315/aos2020.15.2.425>

ABSTRACT

Basal cell adenocarcinoma (BCAC) is a very rare slow-growing malignant basaloid tumour of the minor salivary gland. We reported a case of BCAC of the minor salivary gland of the hard palate occurring in a 56-year-old man. BCAC shares overlapping histopathological features with the other oral basaloid cell neoplasms which carries different prognosis and treatment modality. We emphasised on the histomorphologic features and the role of immunohistochemistry panel in the differential diagnosis of BCAC in incisional biopsies.

Keywords: Basal cell adenocarcinoma; basaloid morphology; hard palate; immunohistochemistry; minor salivary gland

INTRODUCTION

Basal cell adenocarcinoma (BCAC) accounts for 1.6% of all salivary gland neoplasms and 2.9% of all malignant salivary gland neoplasms with the majority of the cases occurring in the parotid gland (Gnepp *et al.*, 2009). The occurrence in minor salivary gland is exceedingly rare (< 1%) and commonly involves the palate, buccal mucosa, nasal cavity, floor of mouth and upper lip. To the best of our knowledge, there are only 25 cases of palatal BCAC

that have been reported in the literature (Jayakrishnan *et al.*, 2003; Toida *et al.*, 2005; Yamagata *et al.*, 2006; Ward *et al.*, 2009; Venkata and Irulandy, 2011; Akiyama *et al.*, 2012; Cuthbertson *et al.*, 2015; Tursun *et al.*, 2019). The majority of BCAC develops de novo but 23% of cases may arise from a pre-existing basal cell adenoma (BCA) (Muller and Barnes, 1996). While BCAC is morphologically similar to BCA, the presence of infiltrative growth, lymphovascular and perineural invasion will help to distinguish between these

two neoplasms. However, the assessment of the lymphovascular and perineural invasion is a limitation in small incisional biopsies. Thus, we aimed to emphasise the importance of histomorphological and immunohistochemical analysis in the diagnosis of BCAC.

CASE REPORT

A 56-year-old Malay male, an active smoker, presented with five years history of a painless hard palate mass which was gradually increasing in size. It was associated with anosmia, unprovoked epistaxis, dysphagia and intermittent difficulty in breathing for the past one year. The patient also experienced pain during mastication for the past month and had lost 15 kg of body weight within four months. The physical examination revealed a midline mass with an irregular border and ulcerated surface at the hard palate extending to the soft palate (Fig. 1a). A few palpable small right cervical lymph nodes were detected. An axial CT scan revealed a locally aggressive large expansile hard palate tumour (10.3 cm × 8.3 cm × 7.6 cm) with local tumour extension, complete nasal occlusion and narrowing of the oral cavity. An MRI of the brain showed no intracranial extension (Figs. 1b and 1c).

An incisional biopsy displayed solid and trabecular nests of basaloid tumour cells with peripheral nuclear palisading (Fig. 2). The tumour cells were monotonous with

oval to round basophilic nuclei and scanty cytoplasm. An intercellular and peripheral membranous pattern of eosinophilic hyalinised material was noted. Foci of squamous eddies were present. A prominent stellate reticulum-like pattern was noted within the tumour islands. Mitosis was about 8 per 10 high power field (HPF). There was no dysplasia of the overlying oral mucosa. There was no evidence of lymphovascular invasion while perineural invasion was non-assessable due to absence of nerve bundle.

The neoplastic cells were positive for pan cytokeratin (CKAE1/AE3), cytokeratin 7 (CK7) (Fig. 3a), P63, cytokeratin 5/6 (CK5/6) and vimentin with focal positivity for P53 (Fig. 3b), epithelial membrane antigen (EMA), S100 and P40. They were negative for CD117 (Fig. 3c), smooth muscle actin (SMA), carcinoembryonic antigen (CEA), CK20 and CD10 stains. The Ki67 proliferative index was about 10% (Fig. 3d). Increase in mitotic count and Ki67 proliferative index and positivity of P53 gave a final diagnosis of BCAC.

Subsequently, the patient underwent right total maxillectomy, left partial maxillectomy, right modified radical neck dissection and left selective neck dissection. A diagnosis of BCAC was confirmed. Post-operatively, the patient underwent adjuvant radiotherapy with tumour doses of 60 Gy delivered by fraction of 1 Gy, 5 days a week for 6 weeks. There was no evidence of recurrence after one year of follow-up since the radiotherapy.




Fig. 1 (a) A large fungating ulcerated mass of the hard palate extending posteriorly; (b) Axial view of MRI of brain shows there is presence of large multilobulated mass with hypo-to-isointense signal on T1; (c) Heterogenous hyperintense signal on T2 and heterogeneously enhanced post contrast. The mass extends anterosuperiorly to abut the frontal sinus and involve the right maxillary sinus, anterior ethmoid air cells, right posterior ethmoid air cells, sphenoid sinus and bilateral nasal cavities.




Fig. 2 Histopathological image of the incisional biopsy: (a) The basaloid tumour cells are arranged in infiltrating anastomosing trabecular pattern. There is squamous differentiation seen (black arrow); (b) The tumour cells are circumscribed and arranged in solid pattern (H&E stain, $\times 40$); (c) The peripheral palisading by smaller cells with scant cytoplasm and round to oval deeply basophilic nuclei are appreciated (H&E stain, $\times 400$); (d) There are eosinophilic basement membrane-like materials (blue arrow) seen within the tumour (H&E stain, $\times 400$).




Fig. 3 Immunohistochemical findings of the incisional biopsy: (a) The tumour cells are positive for CK7; (b) Focal positivity for P53; (c) Negative for CD117; (d) Ki-67 proliferative index of 10% (Magnification $\times 400$).

DISCUSSION

BCAC of minor salivary gland is extremely rare. It typically occurs in adults in their sixth or seventh decade of life and has no gender predominance (Fonseca *et al.*, 2017). The patients usually presented with a slow growing painless mass that had been present for weeks and could be up to 10 years (Jayakrishnan *et al.*, 2003). BCAC have been reported to present with enhancing mass within the salivary gland on CT scan examination (Warrick *et al.*, 2000). Whereas, on MRI examination, BCAC reportedly show a mean apparent diffusion coefficient (ADC) value of 0.96 ± 0.29 (SD) which can be used to distinguish it from

its benign counterpart (Habermann *et al.*, 2009).

It is a challenge to differentiate BCAC of minor salivary glands with other basaloid neoplasms in a simple incisional biopsy due to overlapping microscopic features. Histomorphological analysis with a panel of immunohistochemical stains will help in determining the accurate diagnosis of BCAC. The histological differential diagnoses include BCA, adenoid cystic carcinoma (AdCC), intra-oral basal cell carcinoma (IOBCC), basaloid squamous cell carcinoma (BSCC) and basal cell ameloblastoma (Bajpai and Pardhe, 2017).

On histopathological examination, the tumour may exhibit solid, tubular, trabecular, cribriform and membranous patterns. The solid pattern is the most commonly encountered pattern in BCAC. Microscopically, it has a dual population of cells, comprising small, dark basaloid cells with scanty cytoplasm, and larger polygonal cells with eosinophilic to amphophilic cytoplasm and pale basophilic nuclei. Stellate reticulum-like pattern and squamous differentiation may be observed. Depositions of eosinophilic basement membrane are seen within and surrounding the tumour nests. Mitotic figures of more than 4 per 10 HPF has been reportedly used as a feature to indicate malignancy (Nagao *et al.*, 1998). Perineural and vascular invasion are found in approximately a quarter of cases (Parashar *et al.*, 2007).

BCAC stains for both epithelial and myoepithelial immunohistochemistry markers, highlighting the dual population of cells. However, the expression for BCAC is non-specific, variable and dependent on the patterns of growth. Thus, a panel of immunohistochemistry markers is an important complementary in the diagnostic process. The epithelial markers that are typically expressed in BCAC include CKAE1/AE3, CK7, CK5/6, CEA and EMA. The markers of myoepithelial differentiation such as SMA, S100, P63 and vimentin may be expressed in BCAC particularly by cells at the periphery of tumour nests (Williams *et al.*, 1993; Kim *et al.*, 1997; Andreadis *et al.*, 2005; Farrell and Chang, 2007). CEA stain was negative in the present case as well as in several other case reports (Raslan *et al.*, 1995; Parashar *et al.*, 2007; Sarafraz *et al.*, 2015). Although SMA is a marker of myoepithelial differentiation, it has been reported as negative in several reports, including the present one (Andreadis *et al.*, 2005; Farrell and Chang, 2007; Parashar *et al.*, 2007; Jung *et al.*, 2013).

BCAC is distinguished from BCA by means of invasion of local structures, and perineural as well as lymphovascular invasion. Nagao

et al. (1998) described Ki-67 proliferative index of greater than 5% as a strong indication of malignancy, despite the absence of infiltrative growth, while Yamagata *et al.* (2006) suggested a cut-off point of 10%. The lack of P53 immunoreactivity in BCA may also be useful in differentiating it from its malignant counterpart.

The cribriform-like pattern of BCAC is rarely observed although it can mimic AdCC. The major distinguishing factor is the cytomorphic features of AdCC which include the presence of pale, clear cells with dark hyperchromatic angulated nuclei, absence of peripheral palisading, higher mitotic activity and necrosis. Strong positivity of CD117 is a recognised marker for AdCC (Jung *et al.*, 2013).

Unlike in BCAC, the squamous differentiation in BSCC involves the mucosal epithelium, which may demonstrate dysplasia or carcinoma in-situ. BSCC has far greater mitotic activity than BCAC and usually demonstrate a strong p53 and high Ki67 immunoreactivity. BSCC is negative for CK7, CK20, S100 protein and vimentin as compared to BCAC (Andreadis *et al.*, 2005).

Woods *et al.* (2014) had described a case of IOBCC involving the hard palate, with history of painful erythematous growth of one-year duration. The histological features of IOBCC are similar to its cutaneous counterpart. However, the current case is lacking the usual feature of IOBCC, which is the prominent artefactual cleft from the surrounding stroma. Furthermore, the mitotic figures and apoptotic bodies are significantly higher in IOBCC as compared to BCAC. Immunohistochemically, IOBCC is positive for the cytokeratin, P63, P53 and negative for EMA (Shumway *et al.*, 2011; Woods *et al.*, 2014). Leon *et al.* (2006) reported SMA is positive in 89% of basal cell carcinoma cases in the oral and maxillofacial region with the Ki-67 proliferative index in between 6% to 35%. Yada *et al.* (2004) reported a strong expression of CD10 in 86% cases of IOBCC, which was negative in the present case.

Ameloblastoma of basal cell type is the least common histological variant of the ameloblastoma, accounting for 2.02% of the cases (Reichart *et al.*, 1995). We considered the peripheral ameloblastoma of basal cell type as a differential diagnosis because of the basaloid feature of the tumour cell despite the lack peripheral gingival soft tissue involvement in the present case. Histologically, the tumour exhibits nests of basaloid cells that shows dark basophilic nuclei with little cytoplasm and peripheral palisading. The stellate reticulum-like areas in the central portion of tumour nest which is the feature of ameloblastoma is absent in this variant and the areas are occupied by the basaloid cells. They are negative for CK7, EMA and CD117 (Sridhar *et al.*, 2015). Furthermore, the site for this case is not consistent with odontogenic neoplasm.

BCAC is a low-grade malignant tumour, with a good long-term prognosis (Eveson and Thompson, 2012). The distant metastasis and disease related death are uncommon in BCAC. However, it is a locally destructive and tends to recur (Yamagata *et al.*, 2006). Thus, a complete surgical resection with wide margins is warranted as the primary treatment for BCAC. Frozen section is recommended to assess the margins intraoperatively to ensure the complete surgical resection (Cuthbertson *et al.*, 2015). With the adequate resection, additional measure is not necessary. Routine neck dissection is indicated only when the regional lymph node is involved and the adjuvant radiotherapy is recommended for cases with close or positive resected margins (Farrell and Chang, 2007). BCAC involving the minor salivary gland has a higher recurrence rate and poorer prognosis due to poor resectability of the tumour caused by its location (Gnepp *et al.*, 2009). The other poor prognostic factors of BCAC include advanced stage at presentation, residual tumour at surgery and tumour recurrence.

CONCLUSION

BCAC of the minor salivary gland is a rare salivary gland tumour. Histomorphologic features with the aid of a panel of immunohistochemical analysis comprising of CK7, CK5/6, vimentin, S100, P63, P53, CD117 and Ki67 in BCAC is helpful in establishing the diagnosis of BCAC.

REFERENCES

- Akiyama K, Karaki M, Hosikawa H, Mori N (2012). A massive basal cell adenocarcinoma of the palatal minor salivary gland that progressed into the pterygopalatine fossa. *Int J Oral Maxillofac Surg*, **41**(4): 444–447. <https://doi.org/10.1016/j.ijom.2011.10.013>
- Andreadis D, Nomikos A, Epivatianos A, Pouloupoulos A, Barbatis C (2005). Basaloid squamous cell carcinoma versus basal cell adenocarcinoma of the oral cavity. *Pathology*, **37**(6): 560–563. <https://doi.org/10.1080/00313020500368048>
- Bajpai M, Pardhe N (2017). An insight into the histopathology of oral neoplasms with basaloid morphology and a working classification. *Philipp J Pathol*, **2**(2): 20–24. <https://doi.org/10.21141/PJP.2017.019>
- Cuthbertson DW, Raol N, Hicks J, Green L, Parke R (2015). Minor salivary gland basal cell adenocarcinoma: A systematic review and report of a new case. *JAMA Otolaryngol Head Neck Surg*, **141**(3): 276–283. <https://doi.org/10.1001/jamaoto.2014.3344>
- Eveson JW, Thompson LDR (2012). Malignant neoplasms of the salivary glands. In: Thompson LDR (ed.), *Head and Neck Pathology: A Volume in the Series Foundations in Diagnostic Pathology*, 2nd edn. Philadelphia: Saunders Elsevier, pp. 267–334.

- Farrell T, Chang YL (2007). Basal cell adenocarcinoma of minor salivary glands. *Arch Pathol Lab Med*, **131**(10): 1602–1604.
- Fonseca I, Gnepp DR, Seethala R, Simpson RHW, Vielh P, Williams MD (2017). Tumours of salivary glands. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (eds.), *WHO Classification of Head and Neck Tumours*, 4th edn. Lyon: International Agency for Research on Cancer (IARC), pp. 169–170.
- Gnepp DR, Henley JD, Simpson RH, Eveson J (2009). Salivary and lacrimal glands. In: Gnepp DR (ed.), *Diagnostic Surgical Pathology of the Head and Neck*, 2nd edn. Philadelphia: Saunders Elsevier, pp. 459–461.
- Habermann CR, Arndt C, Graessner J, Diestel L, Petersen KU, Reitmeier F *et al.* (2009). Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: Is a prediction of different histologic subtypes possible? *AJNR Am J Neuroradiol*, **30**(3): 591–596. <https://doi.org/10.3174/ajnr.A1412>
- Jayakrishnan A, Elmalah I, Hussain K, Odell EW (2003). Basal cell adenocarcinoma in minor salivary glands. *Histopathology*, **42**(6): 610–614. <https://doi.org/10.1046/j.1365-2559.2003.01651.x>
- Jung MJ, Roh JL, Choi SH, Nam SY, Kim SY, Lee SW *et al.* (2013). Basal cell adenocarcinoma of the salivary gland: A morphological and immunohistochemical comparison with basal cell adenoma with and without capsular invasion. *Diagn Pathol*, **8**: 171. <https://doi.org/10.1186/1746-1596-8-171>
- Kim KI, Oh HE, Mun JS, Kim CH, Choi JS (1997). Basal cell adenocarcinoma of the salivary gland: A case report. *J Korean Med Sci*, **12**(5): 461–464. <https://doi.org/10.3346/jkms.1997.12.5.461>
- Leon A, Ceașu Z, Ceașu M, Ardeleanu C, Mehedinți T (2006). Assessment of the aggressive feature of basal cell carcinoma in the oral and maxillofacial region. *OHDMBSC*, **5**(4): 62–67.
- Muller S, Barnes L (1996). Basal cell adenocarcinoma of the salivary glands. Report of seven cases and review of the literature. *Cancer*, **78**(12): 2471–2477.
- Nagao T, Sugano I, Ishida Y, Hasegawa M, Matsuzaki O, Konno A *et al.* (1998). Basal cell adenocarcinoma of the salivary glands: Comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2. *Cancer*, **82**(3): 439–447. [https://doi.org/10.1002/\(SICI\)1097-0142\(19980201\)82:3<439::AID-CNCR3>3.0.CO;2-K](https://doi.org/10.1002/(SICI)1097-0142(19980201)82:3<439::AID-CNCR3>3.0.CO;2-K)
- Parashar P, Baron E, Papadimitriou JC, Ord RA, Nikitakis NG (2007). Basal cell adenocarcinoma of the oral minor salivary glands: Review of the literature and presentation of two cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, **103**(1): 77–84. <https://doi.org/10.1016/j.tripleo.2005.12.021>
- Raslan WF, Leonetti JP, Sawyer DR (1995). Basal cell adenocarcinoma of the parotid gland: A case report with immunohistochemical, ultrastructural findings and review of the literature. *J Oral Maxillofac Surg*, **53**(12): 1457–1462. [https://doi.org/10.1016/0278-2391\(95\)90677-0](https://doi.org/10.1016/0278-2391(95)90677-0)
- Reichart PA, Philipsen HP, Sonner S (1995). Ameloblastoma: Biological profile of 3677 cases. *Eur J Cancer B Oral Oncol*, **31B**(2): 86–99. [https://doi.org/10.1016/0964-1955\(94\)00037-5](https://doi.org/10.1016/0964-1955(94)00037-5)

- Sarafraz Z, Azarain MH, Moghimi M, Musavi SA (2015). Basal cell adenocarcinoma of the parotid gland in an elderly Iranian woman and review of the literature. *Otolaryngol (Sunnyvale)*, **5**(1): 1000180. <https://doi.org/10.4172/2161-119X.1000180>
- Shumway BS, Kalmar JR, Allen CM, Rawal YB (2011). Basal cell carcinoma of the buccal mucosa in a patient with nevroid basal cell carcinoma syndrome. *Int J Surg Pathol*, **19**(3): 348–354. <https://doi.org/10.1177/1066896908329596>
- Sridhar M, Bhaskar Reddy LR, Kharat S, Mahesh BS, Gandhi L, Mahendra A *et al.* (2015). Basal cell ameloblastoma: A rare histological variant of an uncommon tumor. *Niger J Surg*, **21**(1): 66–69. <https://doi.org/10.4103/1117-6806.152730>
- Toida M, Shimokawa K, Makita H, Kato K, Kobayashi A, Kusunoki Y *et al.* (2005). Intraoral minor salivary gland tumors: A clinicopathological study of 82 cases. *Int J Oral Maxillofac Surg*, **34**(5): 528–532. <https://doi.org/10.1016/j.ijom.2004.10.010>
- Tursun R, Alsuwied D, Green JM III, Melville J (2019). Palatal basal cell adenocarcinoma from misdiagnosis to cure: A unique case report and review. *J Oral Maxillofac Surg*, **77**(1): 100–108. <https://doi.org/10.1016/j.joms.2018.08.003>
- Venkata V, Irulandy P (2011). The frequency and distribution pattern of minor salivary gland tumors in a government dental teaching hospital, Chennai, India. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, **111**(1): 32–39. <https://doi.org/10.1016/j.tripleo.2010.08.019>
- Ward BK, Seethala RR, Barnes EL, Lai SY (2009). Basal cell adenocarcinoma of a hard palate minor salivary gland: Case report and review of the literature. *Head Neck Oncol*, **1**: 41. <https://doi.org/10.1186/1758-3284-1-41>
- Warrick PD, Irish JC, Mancer K, Dardick I, Pynn BR, Gullane P (2000). Basal cell adenocarcinoma: A rare malignancy of the salivary glands. *J Otolaryngol*, **29**(2): 102–109.
- Williams SB, Ellis GL, Auclair PL (1993). Immunohistochemical analysis of basal cell adenocarcinoma. *Oral Surg Oral Med Oral Pathol*, **75**(1): 64–69. [https://doi.org/10.1016/0030-4220\(93\)90408-v](https://doi.org/10.1016/0030-4220(93)90408-v)
- Woods TR, Cohen DM, Islam MN, Kratochvil FJ, Stewart JCB, Reeder SL *et al.* (2014). Intraoral basal cell carcinoma, a rare neoplasm: Report of three new cases with literature review. *Head Neck Pathol*, **8**(3): 339–348. <https://doi.org/10.1007/s12105-013-0505-5>
- Yada K, Kashima K, Daa T, Kitano S, Fujiwara S, Yokoyama S (2004). Expression of CD10 in basal cell carcinoma. *Am J Dermatopathol*, **26**(6): 463–471. <https://doi.org/10.1097/00000372-200412000-00004>
- Yamagata K, Oka K, Yoshida H, Yanagawa T, Onizawa K, Yusa H *et al.* (2006). Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: A case report. *Pathol Res Pract*, **202**(6): 475–480. <https://doi.org/10.1016/j.prp.2005.12.009>